JP2013512268A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013512268A5 JP2013512268A5 JP2012541422A JP2012541422A JP2013512268A5 JP 2013512268 A5 JP2013512268 A5 JP 2013512268A5 JP 2012541422 A JP2012541422 A JP 2012541422A JP 2012541422 A JP2012541422 A JP 2012541422A JP 2013512268 A5 JP2013512268 A5 JP 2013512268A5
- Authority
- JP
- Japan
- Prior art keywords
- mitotic checkpoint
- compounds
- schmidt
- present
- inhibition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000017205 mitotic cell cycle checkpoint Effects 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 231100001075 aneuploidy Toxicity 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 150000008523 triazolopyridines Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09075534.9 | 2009-11-30 | ||
| EP09075534A EP2343295A1 (en) | 2009-11-30 | 2009-11-30 | Triazolopyridine derivates |
| PCT/EP2010/068298 WO2011064328A1 (en) | 2009-11-30 | 2010-11-26 | Triazolopyridine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013512268A JP2013512268A (ja) | 2013-04-11 |
| JP2013512268A5 true JP2013512268A5 (https=) | 2014-01-09 |
| JP5805654B2 JP5805654B2 (ja) | 2015-11-04 |
Family
ID=42027882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012541422A Expired - Fee Related JP5805654B2 (ja) | 2009-11-30 | 2010-11-26 | トリアゾロピリジン誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20130121994A1 (https=) |
| EP (2) | EP2343295A1 (https=) |
| JP (1) | JP5805654B2 (https=) |
| CN (1) | CN102753547B (https=) |
| CA (1) | CA2782012A1 (https=) |
| ES (1) | ES2532655T3 (https=) |
| WO (1) | WO2011064328A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2343297A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
| UY33452A (es) | 2010-06-16 | 2012-01-31 | Bayer Schering Pharma Ag | Triazolopiridinas sustituidas |
| TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| US9284317B2 (en) | 2010-12-17 | 2016-03-15 | Bayer Intellectual Property Gmbh | Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors |
| JP5822944B2 (ja) | 2010-12-17 | 2015-11-25 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための２置換イミダゾピラジン |
| CN103415518A (zh) | 2010-12-17 | 2013-11-27 | 拜耳知识产权有限责任公司 | 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的咪唑并吡嗪 |
| ES2530802T3 (es) | 2010-12-17 | 2015-03-06 | Bayer Ip Gmbh | Imidazopirazinas 6-tiosustituidas para uso como inhibidores de MPS-1 y TKK en el tratamiento de trastornos hiperproliferativos |
| JP2013545779A (ja) | 2010-12-17 | 2013-12-26 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン |
| CA2821834A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Intellectual Property Gmbh | 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| EP2691375B1 (en) | 2011-03-31 | 2016-03-16 | Bayer Intellectual Property GmbH | Substituted benzimidazoles as mps-1 kinase inhibitors |
| ES2545135T3 (es) | 2011-04-06 | 2015-09-08 | Bayer Pharma Aktiengesellschaft | Imidazopiridinas sustituidas y compuestos intermedios de las mismas |
| WO2012160029A1 (en) | 2011-05-23 | 2012-11-29 | Bayer Intellectual Property Gmbh | Substituted triazolopyridines |
| UA112096C2 (uk) * | 2011-12-12 | 2016-07-25 | Байєр Інтеллектуал Проперті Гмбх | Заміщені триазолопіридини та їх застосування як інгібіторів ttk |
| CN104284896B (zh) | 2012-03-14 | 2016-06-01 | 拜耳知识产权有限责任公司 | 取代的咪唑并哒嗪 |
| CA2878481A1 (en) | 2012-07-10 | 2014-01-16 | Bayer Pharma Aktiengesellschaft | Method for preparing substituted triazolopyridines |
| WO2014020041A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| WO2014020043A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| CN103965199B (zh) * | 2013-02-02 | 2017-07-07 | 广东东阳光药业有限公司 | 一种芳杂环化合物、包含它的药物组合物及其用途 |
| AR096469A1 (es) * | 2013-06-06 | 2015-12-30 | Bayer Pharma AG | Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas |
| HK1219879A1 (zh) | 2013-06-11 | 2017-04-21 | Bayer Pharma Aktiengesellschaft | 用於治疗癌症的包含mps-1激酶抑制剂和有丝分裂抑制剂的组合 |
| RS56034B1 (sr) * | 2013-06-11 | 2017-09-29 | Bayer Pharma AG | Derivati prolekova supstituisanih triazolopiridina |
| EP2860177A3 (en) | 2013-09-20 | 2015-06-10 | Bayer Intellectual Property GmbH | Synthesis of functionalized arenes |
| FI3283642T3 (fi) | 2015-04-17 | 2024-01-11 | Crossfire Oncology Holding B V | Prognostisia biomarkkereita ttk-inhibiittorikemoterapiaan |
| GB201522532D0 (en) * | 2015-12-21 | 2016-02-03 | Cancer Rec Tech Ltd | Novel pyrrolo[3,2-c]pyridine-6-amino derivatives |
| CN107641118B (zh) * | 2016-07-22 | 2020-11-06 | 爱科诺生物医药股份有限公司 | 具有细胞坏死抑制活性的化合物及其组合物和应用 |
| NZ780966A (en) | 2019-04-18 | 2026-02-27 | Univ Johns Hopkins | Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a] pyridine derivatives and use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| MX2007001943A (es) | 2004-08-17 | 2007-05-09 | Galderma Res & Dev | Nuevos compuestos biaromaticos activadores de los receptores del tipo receptor activado del proliferador de peroxisoma (ppar) y su uso en composiciones cosmeticas o farmaceuticas. |
| JP5336375B2 (ja) * | 2006-08-30 | 2013-11-06 | セルゾーム リミテッド | キナーゼ阻害剤としてのトリアゾール誘導体 |
| US8053574B2 (en) * | 2007-07-18 | 2011-11-08 | Novartis Ag | Organic compounds |
| MX2010002115A (es) * | 2007-08-23 | 2010-06-01 | Aztrazeneca Ab | 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos. |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| MX2010005700A (es) * | 2007-11-27 | 2010-06-11 | Cellzome Ltd | Amino triazoles como inhibidores pi3k. |
| WO2010092015A1 (en) * | 2009-02-10 | 2010-08-19 | Cellzome Limited | Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors |
| SG173610A1 (en) * | 2009-02-13 | 2011-09-29 | Fovea Pharmaceuticals Sa | [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors |
-
2009
- 2009-11-30 EP EP09075534A patent/EP2343295A1/en not_active Withdrawn
-
2010
- 2010-11-26 JP JP2012541422A patent/JP5805654B2/ja not_active Expired - Fee Related
- 2010-11-26 CA CA2782012A patent/CA2782012A1/en not_active Abandoned
- 2010-11-26 EP EP10787724.3A patent/EP2507236B1/en not_active Not-in-force
- 2010-11-26 WO PCT/EP2010/068298 patent/WO2011064328A1/en not_active Ceased
- 2010-11-26 ES ES10787724.3T patent/ES2532655T3/es active Active
- 2010-11-26 US US13/512,721 patent/US20130121994A1/en not_active Abandoned
- 2010-11-26 CN CN201080061523.7A patent/CN102753547B/zh not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013512268A5 (https=) | ||
| JP2013512263A5 (https=) | ||
| JP2013503824A5 (https=) | ||
| JP2013512264A5 (https=) | ||
| Duan et al. | EZH2: a novel target for cancer treatment | |
| Kepp et al. | ATP and cancer immunosurveillance | |
| Do et al. | Wee1 kinase as a target for cancer therapy | |
| Wang et al. | Aberrant regulation of FBW7 in cancer | |
| Jhaveri et al. | HSP90 inhibitors for cancer therapy and overcoming drug resistance | |
| EP3746436A1 (en) | Fused ring compounds | |
| TW202045181A (zh) | 細胞週期蛋白依賴性激酶2生物標記物及其用途 | |
| JP2021502388A (ja) | Ａｓｈ１ｌ阻害剤及びそれを用いた治療方法 | |
| JP2016533366A5 (https=) | ||
| EP4335511A3 (en) | Small molecule trail gene induction by normal and tumor cells as an anticancer therapy | |
| JP2016501221A5 (https=) | ||
| AU2018212647A1 (en) | Combination therapy involving diaryl macrocyclic compounds | |
| JP2017500338A5 (https=) | ||
| JP2015512943A5 (https=) | ||
| TW200808802A (en) | Imidazopyrazines as protein kinase inhibitors | |
| JP2015508103A5 (https=) | ||
| BR112014027337A2 (pt) | composições orgânicas para tratar doenças relacionadas com kras | |
| KR20180130575A (ko) | 정지 세포 표적화 및 유사분열 억제제를 이용하는 신생물 치료를 위한 조합 | |
| Zhang et al. | Targeting PI3K signaling in Lung Cancer: Advances, challenges and therapeutic opportunities | |
| JP2014532751A5 (https=) | ||
| JP2013521314A5 (https=) |